A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Apr 2027 → Sep 2028
See other at-risk trials from Eli Lilly

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 2027 to Sep 2028
  2. Eligibility criteria expanded, about 14 words
    • Site details revised at 4 of 46 sites
  3. Site details revised at 1 of 46 sitesv20
  4. Site details revised at 2 of 46 sitesv19
  5. Site details revised at 2 of 46 sitesv18
Show 2 earlier versionsHide 2 earlier versions
  1. Site details revised at 1 of 46 sitesv17
  2. Site details revised at 2 of 46 sitesv16
  1. Primary completion pushed from Feb 2027 to Apr 2027
    • Study completion pushed from Dec 2029 to Feb 2030
    • Study sites: 45 to 46
    v15
  2. Recruitment openedv14 Show 4 more changesShow less
    • Enrollment increased: 360 → 460 participants
    • Start date changed from estimate of Apr 2026 to Apr 17, 2026
    • Eligibility criteria expanded, about 49 words
    • Site details revised at 45 of 45 sites
  3. Study sites: 44 to 45v13
  4. Start date: Feb 2026 to Apr 2026v12
  5. Study sites: 40 to 44v11
  6. Study sites: 33 to 40v10
  7. Study sites: 32 to 33v9
  8. Study sites: 28 to 32v8
  9. Study sites: 22 to 28v7
  10. Study sites: 19 to 22v6
  11. Study sites: 15 to 19v5
  12. Study sites: 13 to 15v4
  13. Study sites: 9 to 13v3
  14. Re-verified, no change to tracked fieldsv2
  15. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
DLBCL
706 trials monitored
See 46 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Trial Details
NCT Number NCT07226843
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Related terms Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov